Regarding the interventional setting, the addition of a selective COX-2 inhibitor to the standard treatment of cancer patients in the palliative, adjuvant and neoadjuvant settings was evaluated in an important meta-analysis [97]. This evidence concerns the gene PTGS2 and cancer.